FirsthandHealth
medRxiv PreprintsInternational19 November 2026

Anti-Ro52 autoantibodies modulate the transcriptomic effects of autoantibodies targeting intracellular autoantigens

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Objective: Ro52/TRIM21 is a cytoplasmic protein that binds intracellular antibodies and drives their proteasomal degradation. Autoantibodies targeting Ro52 frequently co-occur with myositis-specific autoantibodies, including anti-MDA5, and patients with both autoantibodies have greater disease severity and interstitial lung disease risk. We previously demonstrated that internalized anti-MDA5 autoantibodies promote interferon-stimulated gene expression in cultured myoblasts. Here, we investigated the interactions between anti-Ro52 and coexisting autoantibodies, including anti-MDA5. Methods: Pri
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.